• Indications
  • Open Access TIMES Journals
Login Register
Login Register
Indications
  • Oncology · Hematology
  • Spine Surgery
  • Cardiovascular
  • Diabetes + Endocrinology
  • Pneumology
  • Ophthalmology
  • Gynecology · Urology
  • Dermatology · Immunology · Rheumatology
  • Neurology · Psychiatry
  • Gastroenterology
  • Infectiology · Anesthesiology · Pain
  • Primary Care
Open Access TIMES Journals
  • Oncology · Hematology
  • Spine Surgery
  • Cardiovascular
  • Diabetes + Endocrinology
  • Pneumology
  • Ophthalmology
  • Gynecology · Urology
  • Dermatology · Immunology · Rheumatology
  • Neurology · Psychiatry
  • Gastroenterology
  • Infectiology · Anesthesiology · Pain
  • Primary Care
Oncology · Hematology

Oncology · Hematology

Case Reports
Expert Opinions
Congress News
E-Learning
Webinar
Faculty
healthbook TIMES
Homepage >
Oncology · Hematology >
Articles

Determinants of late metastases in renal cell carcinoma

Genitourinary Cancer
Share:
Do you want to read an article? Please log in or register.
Register for Free
Remember me
Forgot password? Click here

Related content

Genitourinary Cancer
Impact of brain metastases on systemic renal cell carcinoma treatment outcomes: A systematic literature review
Cancer Treat Rev
Charnley N, Fife K, Heng DYC, Larkin J, McGrane J, Négrier S, Vasudev N, Venugopal B, Chisholm A, Ogareva A, Prendergast Á, Albiges L
doi: 10.1016/j.ctrv.2025.103024
Genitourinary Cancer
Longitudinal Evaluation of Clear-cell Renal Cell Carcinoma in von Hippel-Lindau Disease
Eur Urol
Linehan WM, Pinto CA, Liu Y, Choo K, Gautam R, Fox C, Roy A, Li M, Bosan R, Nielsen D, Ryan B, Blake Z, Reynolds K, Rompre-Brodeur A, Pinto PA, Vocke C, Gurram S, Ball MW, Perini R, Srinivasan R
doi: 10.1016/j.eururo.2025.03.002
Genitourinary Cancer
First-Line Therapy For Advanced Non-Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
JAMA Oncol
Petrelli F, Verri E, Ghidini A, Vavassori I, Lonati V, Nolè F, Dottorini L
doi: 10.1001/jamaoncol.2025.1891
Genitourinary Cancer
Real-world comparison of cabozantinib and sunitinib in advanced non-clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group
Int J Cancer
Şahin G, Tüzün EK, Güzel HG, Guliyev M, Dişli AK, Yazıcı M, Yıldız O, Güneş TK, Alkan S, Kahraman EG, Özel GS, İçli MC, Şahin E, Muğlu H, Acar C, Tunbekici S, Yüksel HÇ, Yücel H, Kahya BU, Kitaplı S, Büyükşimşek M, İpek ŞA, Dama PE, Usta EA, Yılmaz M, Aşık E, Özalp FR, Savsar MG, Kocaaslan E, Sim S, Ağaoğlu AB, Çamöz ES, Demir T, Uyar GC, Yıldırım A, Çınkır HY, Salim DK, Doğu GG, Alan Ö, Bayram E, Karaçin C, Güç ZG, Ekinci F, Eryılmaz MK, Semiz HS, Ünal OÜ, Göksu SS, Öztürk B, İnanç M, Uygun K, Hacıbekiroğlu İ, Erçolak V, Kara İO, Yazıcı O, Bilici A, Tanrıverdi Ö, Karaca B, Erman M, Gökmen E, Göker E, Yıldırım HÇ
doi: 10.1002/ijc.70165
Genitourinary Cancer
Comparative efficacy and safety of ablative therapies in the management of primary localised renal cell carcinoma: a systematic review and meta-analysis
Lancet Oncol
Huang RS, Chow R, Benour A, Chen D, Boldt G, Wallis CJD, Swaminath A, Simone CB 2nd, Lock M, Raman S
doi: 10.1016/S1470-2045(24)00731-9
Genitourinary Cancer
Non-surgical management vs active treatment in T1a renal cell carcinoma: a population-based study
BJU Int
Hashim BM, Rosenblad AK, Lundgren PO, Lundstam S, Ljungberg B
doi: 10.1111/bju.70074
Genitourinary Cancer
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial
Lancet Oncol
Zhou A, Shen P, Li J, Qu W, Wang Z, Ren X, Li Y, Jiang S, Li G, Zeng Y, Qin W, Wu J, Chen P, Zhou F, Guo H, Ji Z, Wang Y, He Z, Wu J, Shi B, Liu L, Yao X, Ma L, Liu Z, Gou X, Fu B, Wang S, Jiang K, Chong T, Tu X, Zhang X, Yu D, Rexiati M, Xue X, Fei J, Wan J, Jia L, He Y, Cui T, Yang AQ, Guo J, Sheng X
doi: 10.1016/S1470-2045(25)00343-2
Genitourinary Cancer
Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial
Lancet Oncol
Powles T, Choueiri TK, Albiges L, Peltola K, de Velasco G, Burotto M, Suarez C, Ghatalia P, Iacovelli R, Lam ET, Verzoni E, Gümüş M, Stadler WM, Kollmannsberger C, Melichar B, Venugopal B, Gross-Goupil M, Poprach A, De Santis M, Rizzo M, Shinde R, Saretsky TL, He L, Perini RF, Vickery D, Rini B
doi: 10.1016/S1470-2045(25)00032-4
Genitourinary Cancer
Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium
Lancet Oncol
Blackmur JP, van der Mijn JCK, Warren AY, Browning L, Burgers F, Hirsch MS, Kapur P, Mehra R, Rao P, Signoretti S, Bex A, Stewart GD, van Montfoort ML, Jones JO, International Neoadjuvant Kidney Cancer Consortium
doi: 10.1016/S1470-2045(25)00345-6
  • Contact us
  • About us
  • Privacy Policy & Disclaimer
  • Online Media 2026 Data
  • Imprint
healthbook is a registered trademark. Copyright © 2026 healthbook